TY  - JOUR
A1  - Patil, Sandeep S.
A1  - Gentschev, Ivaylo
A1  - Adelfinger, Marion
A1  - Donat, Ulrike
A1  - Hess, Michael
A1  - Weibel, Stephanie
A1  - Nolte, Ingo
A1  - Frentzen, Alexa
A1  - Szalay, Aladar A.
T1  - Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody
JF  - PLoS One
N2  - Virotherapy using oncolytic vaccinia virus (VACV) strains is one promising new strategy for cancer therapy. We have previously reported that oncolytic vaccinia virus strains expressing an anti-VEGF (Vascular Endothelial Growth Factor) single-chain antibody (scAb) GLAF-1 exhibited significant therapeutic efficacy for treatment of human tumor xenografts. Here, we describe the use of oncolytic vaccinia virus GLV-1h109 encoding GLAF-1 for canine cancer therapy. In this study we analyzed the virus-mediated delivery and production of scAb GLAF-1 and the oncolytic and immunological effects of the GLV-1h109 vaccinia virus strain against canine soft tissue sarcoma and canine prostate carcinoma in xenograft models. Cell culture data demonstrated that the GLV-1h109 virus efficiently infect, replicate in and destroy both tested canine cancer cell lines. In addition, successful expression of GLAF-1 was demonstrated in virus-infected canine cancer cells and the antibody specifically recognized canine VEGF. In two different xenograft models, the systemic administration of the GLV-1h109 virus was found to be safe and led to anti-tumor and immunological effects resulting in the significant reduction of tumor growth in comparison to untreated control mice. Furthermore, tumor-specific virus infection led to a continued production of functional scAb GLAF-1, resulting in inhibition of angiogenesis. Overall, the GLV-1h109-mediated cancer therapy and production of immunotherapeutic anti-VEGF scAb may open the way for combination therapy concept i.e. vaccinia virus mediated oncolysis and intratumoral production of therapeutic drugs in canine cancer patients.
KW  - angiogenesis
KW  - microenvironment
KW  - model
KW  - cancer
KW  - therapy
KW  - pet dogs
KW  - nude-mice
KW  - breast-tumors
KW  - microvascular density
KW  - endothelial growth-factor
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130039
VL  - 7
IS  - 10
ER  - 
TY  - JOUR
A1  - Gentschev, Ivaylo
A1  - Adelfinger, Marion
A1  - Josupeit, Rafael
A1  - Rudolph, Stephan
A1  - Ehrig, Klaas
A1  - Donat, Ulrike
A1  - Weibel, Stephanie
A1  - Chen, Nanhai G.
A1  - Yu, Yong A.
A1  - Zhang, Qian
A1  - Heisig, Martin
A1  - Thamm, Douglas
A1  - Stritzker, Jochen
A1  - MacNeill, Amy
A1  - Szalay, Aladar A.
T1  - Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
JF  - PLoS One
N2  - Virotherapy using oncolytic vaccinia virus (VACV) strains is one promising new strategy for canine cancer therapy. In this study we describe the establishment of an in vivo model of canine soft tissue sarcoma (CSTS) using the new isolated cell line STSA-1 and the analysis of the virus-mediated oncolytic and immunological effects of two different Lister VACV LIVP1.1.1 and GLV-1h68 strains against CSTS. Cell culture data demonstrated that both tested VACV strains efficiently infected and destroyed cells of the canine soft tissue sarcoma line STSA-1. In addition, in our new canine sarcoma tumor xenograft mouse model, systemic administration of LIVP1.1.1 or GLV-1h68 viruses led to significant inhibition of tumor growth compared to control mice. Furthermore, LIVP1.1.1 mediated therapy resulted in almost complete tumor regression and resulted in long-term survival of sarcoma-bearing mice. The replication of the tested VACV strains in tumor tissues led to strong oncolytic effects accompanied by an intense intratumoral infiltration of host immune cells, mainly neutrophils. These findings suggest that the direct viral oncolysis of tumor cells and the virus-dependent activation of tumor-associated host immune cells could be crucial parts of anti-tumor mechanism in STSA-1 xenografts. In summary, the data showed that both tested vaccinia virus strains and especially LIVP1.1.1 have great potential for effective treatment of CSTS.
KW  - breast-tumors
KW  - animal-model
KW  - nude-mice
KW  - cell-line
KW  - in-vitro
KW  - glv-1h68
KW  - cancer
KW  - virotherapy
KW  - dogs
KW  - neutrophils
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-129998
VL  - 7
IS  - 5
ER  -